NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
Chimerix, Inc. (NYSE: CMRX) Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. Shares of Chimerix are trading higher today with strong volume as news of the development of its oral antiviral treatment, CMX001, a nucleotide analog lipid conjugate, brincidofovir, is currently in the phase 3 clinical development process. Shares are trading up almost 12% on the day.
Aeterna Zentaris Inc. (Nasdaq: AEZS) Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. Aeterna Zentaris is trading up almost 25% with almost quadruple its average volume on the day and has traded higher all day after the pre-market conclusion of its meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen; 'confident' that it will complete the confirmatory trial by year-end 2016. The study population will consist of approximately 110 subjects, half with insulin deficiency and half without and the endpoint is validation of a single oral dose of macimorelin for the diagnosis of AGHD.
TimkenSteel Corporation (NYSE: TMST) TimkenSteel Corporation manufactures and sells alloy steel, and carbon and micro-alloy steel products. It operates in two segments, Industrial & Mobile, and Energy & Distribution. Shares of TimkenSteel are trading higher today off double its usual volume in the face of being downgraded by Jeffries one week ago. After a tumultuous 2015, shares appear to be bouncing off its 52 week low of $3.69, showing some signs of a possible bottom in share price. The stock is trading up 19% on the day.
Great Basin Scientific, Inc. (Nasdaq: GBSN) Great Basin Scientific, Inc., a molecular diagnostic testing company, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-acquired infections. This morning, Great Basin announced an update of series C warrant conversions, where about 4.3MM warrants remain unconverted, Company has approximately 60MM unissued, unreserved authorized shares of common stock available for conversion. After opening the trading day down, over the course of the day, shares exploded higher off abnormally heavy volume. After some heavy gains, shares have settled down and are trading up over 8% on the day.
To Receive Free NASDAQ Alerts, Subscribe Today.
About TheStockExpert.com
The Stock Expert is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big news on high volume days. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments.
To receive free text message alerts on your phone, compose a new text message to the number 95577 with the word “STOCKEXPERT”.
Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. The Stock Expert has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. The Stock Expert is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit TheStockExpert.com/disclaimer website for a more detailed discussion of risks and disclosures.
Contact:
Justin Skibinski
The Stock Expert
info@thestockexpert.com
SOURCE: The Stock Expert
